Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Last trade$2.56
Day change-$0.01 (-0.39%)
Day range$2.49 – $2.59
Volume671,851
Market cap$383M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$382.61M
Price / earnings
9.3×
Price / book
3.28×
Price / sales
2.21×
EV / sales
1.77×
EV / EBITDA
7.83×
Profitability
Earnings per share
$0.28
Return on assets
24.82%
Return on equity
35.29%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.1×
Quick ratio
4.1×
Cash ratio
2.13×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$150.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALEC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$162.87M
$3.32M
$1.05M
$6.24M
$3.26M
$7.87M
$3.67M
$54.24M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$162.87M
$3.32M
$1.05M
$6.24M
$3.26M
$7.87M
$3.67M
$54.24M
Selling, general and administrative
$8.99M
$8.25M
$8.11M
$13.34M
$11.52M
$14.4M
$14.73M
$15.03M
Research and development
$30.03M
$19.46M
$17.86M
$32.46M
$29.35M
$27.61M
$33.64M
$46.46M
Total operating expenses
$39.03M
$27.71M
$25.97M
$45.8M
$40.87M
$42.01M
$48.37M
$61.49M
Operating income
$123.84M
-$24.39M
-$24.92M
-$39.57M
-$37.61M
-$34.14M
-$44.7M
-$7.25M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$124.66M
-$22.86M
-$22.93M
-$37.1M
-$34.67M
-$30.52M
-$40.47M
-$2.03M
Income taxes
$60K
$130K
$0
$168K
$0
$0
$0
$48K
Net income
$124.6M
-$22.99M
-$22.93M
-$37.27M
-$34.67M
-$30.52M
-$40.47M
-$2.07M
Net income attributable to common shareholders
$124.6M
-$22.99M
-$23.2M
-$37.27M
-$34.67M
-$30.52M
-$40.54M
-$2.07M
EBITDA
$124.82M
-$23.34M
-$23.84M
-$38.4M
-$36.37M
-$31.81M
-$43.71M
-$6.01M
Basic earnings per share
$1.11
-$0.21
-$0.21
-$0.34
-$0.34
-$0.30
-$0.41
-$0.02
Diluted earnings per share
$1.11
-$0.21
-$0.21
-$0.34
-$0.34
-$0.30
-$0.41
-$0.02
Recent news
Company coverage with links to the original publishers.
IQVIA Holdings (IQV) reported solid Q3 2026 results with R&D Solutions revenues up 8.7% year-over-year and net new bookings growing 15%, while Commercial Solutions revenues grew 6.9%. The company's deployment of 415 AI agents has improved operational efficiency, with adjusted EBITDA rising 8.7% and margins expanding by 20 basis points. Despite strong performance, IQV holds a Zacks Rank #3 (Hold) rating.
Alector (ALEC) has attracted investor interest due to solid improvements in earnings estimates, with consensus estimates rising significantly for both the current quarter and full year. The company currently holds a Zacks Rank #2 (Buy) rating, supported by upward estimate revisions from analysts. The stock has gained 35.3% over the past four weeks, with potential for further upside.
The dementia therapeutics market is experiencing significant growth driven by emerging disease-modifying treatments for early-stage Alzheimer's and promising therapies for other dementia subtypes. With approximately 55 million people globally affected by dementia, the market is shifting toward proactive intervention with drugs like LEQEMBI and KISUNLA leading the way, while the pipeline shows promise with novel agents targeting diverse symptoms and unmet needs.
Alector's Phase 3 clinical trial for latozinemab in frontotemporal dementia failed to meet primary endpoints, causing a 50% stock price drop and triggering a potential shareholder lawsuit.
Biotechnology company Alector announced that its drug latozinemab did not meet safety and efficacy criteria in a Phase 3 clinical trial for treating frontotemporal dementia (FTD) caused by GRN gene variants. Despite increasing progranulin protein levels, the drug did not slow disease progression.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.